Who is on it, and how far along Every drug ChEMBL records acting on LAG3, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved1 Relatlimab Relatlimab SponsorBristol-Myers Squibb ModalityAntibody ActionInhibitor Open trials55 Phase 32 Fianlimab Fianlimab SponsorRegeneron ModalityAntibody ActionInhibitor Open trials35 Favezelimab Favezelimab SponsorMerck & Co. (MSD) ModalityAntibody ActionInhibitor Open trials3 Phase 23 Eftilagimod alfa Eftilagimod alfa SponsorIMMUTEP ModalityOther ActionVaccine antigen Open trials4 Ieramilimab Ieramilimab SponsorNovartis Pharmaceuticals ModalityAntibody ActionInhibitor Open trials0 Tebotelimab Tebotelimab SponsorZai Lab ModalityAntibody ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 6 act as: Lymphocyte activation gene 3 protein inhibitor; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 23 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma Relatlimab Phase 2 Not yet recruiting Medical College of Wisconsin Oct 27, 2026 A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) Fianlimab Phase 2 Not yet recruiting Regeneron Pharmaceuticals Sep 9, 2026 A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Fianlimab Phase 1 Not yet recruiting Memorial Sloan Kettering Cancer Center Jun 16, 2026 Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Relatlimab Phase 2 Not yet recruiting Nationwide Children's Hospital Jun 12, 2026 MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. Relatlimab Phase 2 Recruiting Swiss Cancer Institute May 7, 2026 A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Fianlimab Phase 1 / Phase 2 Not yet recruiting Regeneron Pharmaceuticals May 5, 2026 Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma Fianlimab Phase 2 Not yet recruiting University of California, Irvine Apr 14, 2026 PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma Fianlimab Phase 2 Not yet recruiting M.D. Anderson Cancer Center Apr 6, 2026 ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Relatlimab Phase 2 Recruiting NYU Langone Health Apr 1, 2026 A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Relatlimab Phase 4 Not yet recruiting Bristol-Myers Squibb Mar 9, 2026 A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Fianlimab Phase 2 Not yet recruiting University of Chicago Jan 16, 2026 Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer Fianlimab Phase 2 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Dec 15, 2025 Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Relatlimab Phase 1 / Phase 2 Recruiting University of Wisconsin, Madison Dec 15, 2025 IL-17 Blockade to Decrease irAEs (REPLAY) Relatlimab Phase 1 Recruiting Duke University Nov 20, 2025 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Fianlimab Phase 2 Recruiting Intergroupe Francophone de Cancerologie Thoracique Nov 18, 2025 Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma Relatlimab — Recruiting John Kirkwood Oct 31, 2025 Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer Eftilagimod alfa Phase 2 Not yet recruiting George Washington University Aug 5, 2025 Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) Eftilagimod alfa Phase 3 Active, not recruiting Immutep S.A.S. Dec 10, 2024 Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Eftilagimod alfa Phase 2 Active, not recruiting Maria Sklodowska-Curie National Research Institute of Oncology Nov 13, 2023 A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) Favezelimab Phase 1 / Phase 2 Active, not recruiting Merck Sharp & Dohme LLC May 6, 2023 Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) Favezelimab Phase 1 / Phase 2 Active, not recruiting Merck Sharp & Dohme LLC Jun 24, 2021 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Favezelimab Phase 3 Recruiting Merck Sharp & Dohme LLC Apr 3, 2018 Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors Eftilagimod alfa Phase 1 Active, not recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Aug 17, 2017
Show all 23Diseases most associated with it Open Targets association score, 0 to 1; all associations Melanoma 0.58 Melanoma Value0.58 Open Non-small cell lung carcinoma 0.39 Non-small cell lung carcinoma Value0.39 Colorectal cancer 0.35 Colorectal cancer Value0.35 Open Metastatic colorectal cancer 0.27 Metastatic colorectal cancer Value0.27 Open Autoimmune thyroid disease 0.27 Autoimmune thyroid disease Value0.27 Gastric cancer 0.24 Gastric cancer Value0.24 Open Breast cancer 0.23 Breast cancer Value0.23 Open Head and neck squamous cell carcinoma 0.23 Head and neck squamous cell carcinoma Value0.23 Gastroesophageal junction adenocarcinoma 0.22 Gastroesophageal junction adenocarcinoma Value0.22 Urinary bladder carcinoma 0.22 Urinary bladder carcinoma Value0.22 Gastric neoplasm 0.19 Gastric neoplasm Value0.19 Cancer 0.14 Cancer Value0.14 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630881 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P18627 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets